NCT00962767 2009-08-20Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular RemissionWyeth is now a wholly owned subsidiary of PfizerPhase 3 Completed168 enrolled